STOCK TITAN

BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
BioMarin Pharmaceutical Inc. to host a conference call on April 24, 2024, to discuss first quarter financial results and business update.
Positive
  • None.
Negative
  • None.

SAN RAFAEL, Calif., April 10, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 24, at 4:30 p.m. ET to discuss first quarter 2024 financial results and provide a general business update.

Dial-in Number 
U.S. / Canada Dial-in Number: 888-330-3556
International Dial-in Number: 646-960-0826
Conference Call ID: 1816377

U.S. / Canada Replay Dial-in Number: 800-770-2030
International Replay Dial-in Number: 609-800-9909
Playback ID: 1816377

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/. A replay of the call will be archived on the site for one week following the call.

About BioMarin
Founded in 1997, BioMarin is a global biotechnology Company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of the genetic conditions. BioMarin's unparalleled research and development capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit www.biomarin.com.

Contacts:

Investors           

Media                           

Traci McCarty 

Marni Kottle

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 455-7558                     

(650) 374-2803

                       

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-host-first-quarter-2024-financial-results-conference-call-and-webcast-on-wednesday-april-24-2024-at-430pm-et-302109127.html

SOURCE BioMarin Pharmaceutical Inc.

FAQ

When will BioMarin Pharmaceutical Inc. host a conference call to discuss first quarter financial results?

BioMarin Pharmaceutical Inc. will host a conference call on April 24, 2024, at 4:30 p.m. ET.

Who will host the conference call for BioMarin Pharmaceutical Inc.?

Alexander Hardy, President and Chief Executive Officer of BioMarin, will host the conference call.

Where can interested parties access the live audio webcast of the conference call?

Interested parties can access the live audio webcast of the conference call via the investor section of the BioMarin website.

How long will the replay of the conference call be available on the BioMarin website?

The replay of the conference call will be archived on the BioMarin website for one week following the call.

BioMarin Pharmaceuticals Inc

NASDAQ:BMRN

BMRN Rankings

BMRN Latest News

BMRN Stock Data

15.82B
187.23M
0.84%
100.76%
1.62%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NOVATO

About BMRN

biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment